The emergence of a novel cross-α fibrillar structure,
unlike
the commonly observed sequence-independent cross-β one, of a
22-residue bacterial virulent amphipathic α-helical peptide
of the phenol soluble modulin (PSM) family, PSMα3, with many
deleterious effects on human life, has infused uncertainty to the
paradigm of the intrinsically polymorphic, multivariate, multiphasic,
and cross-sequence–cross-disease entangled protein aggregation
landscape and hence on the identity of the therapeutic target. We,
here, deconvolute the factors contributing to the genesis and hence
the transition of lower to higher order aggregates of PSMα3
in its natural state and three noncanonical designed variants using
conventional and enhanced sampling approach-based atomistic simulations.
PSMα3 shows structural polymorphism with nominal α-helicity,
substantial β-propensity, and dominant random-coil features,
irrespective of the extent of aggregation. Moreover, the individual
features of the overall amphipathicity operate alternatively depending
on the extent and organization of aggregation; the dominance gradually
moves from charged to hydrophobic residues with the progressive generation
of higher order aggregates (dimer to oligomer to fibril) and with
increasing orderedness of the self-assembled construct (oligomer vs
dimer/fibril). Similarly, the contribution of interchain salt bridges
decreases with increasing order of aggregation (dimer to oligomer
to fibril). However, the intrachain salt bridges consistently display
their role in all phases of aggregation. Such phase-independent features
also include equivalent roles of electrostatic and van der Waals forces
on intrachain interactions, sole contribution of van der Waals forces
on interchain cross-talk, and negligible peptide–water relationship.
Finally, we propose a conjugate peptide-based aggregation suppressor
having a single-point proline mutation.